Biogen Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Biogen Inc.Headquarters: Cambridge, 
                        MA, United States
                    
Founded: 1978
Employees: 9,610
CEO: Mr. Michel  Vounatsos

                                show_chart
                                
                                    NASDAQ: BIIB
                                
                                            +0.01%
                                            
Market Cap$39.26 Billion

                        USD as of Jan. 1, 2023
                    
                            history
                            Market Cap History

Biogen Inc. Categories

United States Healthcare Drug Manufacturers—General

United States Healthcare

United States Drug Manufacturers—General

Company Description

Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.

Biogen Inc. market capitalization over time

Evolution of Biogen Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Biogen Inc.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—General

Company	Market Cap (USD)
Johnson & Johnson	$461.85 B
Lilly	$347.61 B
Pfizer	$287.63 B
AbbVie	$285.80 B
Merck	$281.30 B

Sector: Healthcare

Company	Market Cap (USD)
UnitedHealth Group	$495.37 B
Johnson & Johnson	$461.85 B
Lilly	$347.61 B
Novo Nordisk	$304.61 B
Pfizer	$287.63 B

Detailed Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.